IPOs this week : Sept 6 - 10, 2021 (wk 36)

 IPO lockup expirations

• First High-School Education Group (NYSE:FHS) on September 7, 
• Hayward (NYSE:HAYW), Olo Inc (NYSE:OLO), Prometheus Biosciences (NASDAQ:RXDX), JOANN (NASDAQ:JOAN), Longboard Pharmaceuticals (NASDAQ:LBPH), Meatech 3D (NASDAQ:MITC) on September 8. 

Of the group, Olo has posted the biggest gain from its IPO pricing level. 

IPO quiet period expirations

• Eliem Therapeutics (NASDAQ:ELYM), 
• Southern States Bancshares (NASDAQ:SSBK), 
• Dermata Therapeutics (NASDAQ:DRMA) and 
• PetVivo (NASDAQ:PETV).

IPOs this week : Apr 5 - 9, 2021 (wk 14)

IPOs expected to price

• Inspira Technologies Oxy B.H.N. (NASDAQ:IINN) . The Israel-based medtech company is selling 2.8M shares. 

IPO quiet period expirations

• Coupang (NYSE:CPNG) and First High-School Education (NYSE:FHS) on April 5, as well as
• Joann (JOAN), Hayward (NYSE:HAYW), Prometheus Bio (NASDAQ:RXDX) and Longboard Pharma (NASDAQ:LBPH) on April 6. 

IPO lockup expirations

• Presidio Property (NASDAQ:SQFT) on April 5, 
• Aziyo Bioogics (NASDAQ:AZYO) on April 6 and 
• Kronos Bio (NASDAQ:KRON) on April 7. 

Across the Pacific, Trip.com (NASDAQ:TRIP) could launch a secondary listing in Hong Kong that reportedly could be valued at more than $1B.

Ignyta (RXDX) to acquired by Roche (RHHBY) for $1.7B

 

Roche announced Friday that it entered into a definitive merger agreement to fully acquire Ignyta at a price of $27 per share in cash, representing a premium of about 74 percent to its closing price on December 20, for a total transaction value of $1.7 billion.

• Ignyta's lead drug candidate, the oral CNS-active tyrosine kinase inhibitor entrectinib, targets tumours with ROS1 fusions in non-small-cell lung cancer (NSCLC) or NTRK fusions across a broad range of solid tumours. The company, which will continue its operations in San Diego, will be responsible for the ongoing Phase II STARTRK-2 trial of entrectinib in patients with ROS1 fusion-positive advanced NSCLC. Interim results unveiled in October showed that first-line targeted therapy with entrectinib led to confirmed objective response rates (ORR) of 78 percent and 69 percent by investigator and blinded independent central review, respectively.

IPO: March 14, 2014 

In late 2013, Ignyta completed a reverse merger with Infinity Oil & Gas Company, with the combined company focusing solely on Ignyta's business. Prior to that Ignya garnered a few rounds of venture funding, the largest of which was a $5.5 million Series B financing, which, coupled with a $500,000 capital term loan from Silicon Valley Bank, gave the company a $13 million valuation in February 2013.